摘要
目的 :进一步提高中晚期恶性肿瘤患者的生活质量。方法 :从 2 0 0 1年 1月～ 2 0 0 2年 6月 12 0例中晚期恶性肿瘤患者按组间均衡设计分为单纯放疗组 (对照组 )和放射联合参附注射液治疗组 (试验组 ) ,每组 6 0例。评估二组病人放疗结束后的生活质量的改善及局控率。分析放疗前后CD3+、CD4 +、CD4 +/CD8+的变化。结果 :治疗组局控率 (CR)为 78.3 % ,而对照组为 73 .8% ,无显著性差异 (P >0 .0 5 ) ;放疗后对照组CD3+、CD4 +、CD4 +/CD8+降低 ,CD8+增高 ,放疗前后对比有显著性差异 (P <0 .0 1) ,而治疗组放疗前后无显著差异 ;治疗组头晕、乏力缓解率为 81.5 % ,对照组为 44 .8% ,有显著性差异 (P <0 .0 1) ,治疗组骨髓抑制较对照组明显减轻。结论 :在中晚期恶性肿瘤放疗过程中联合使用参附注射液能增强肿瘤患者的免疫功能 ,提高生活质量 ,且副作用轻 ,但不能提高局控率。
Objective:To further improve the life quality of patients with middle or advanced carcinoma. Methods:From 2001 to 2002,120 patients with middle or advanced carcinoma were divided equally into two groups: control group(radiother apyalone), test group (combination of radiotherapy with SF injection), we assessed the life quality of patients, evaluated the local control rate of the two groups by the end of radiotherapy, analyzed the variation of CD3 +,CD4 +, CD4 +/CD8 + before radiotherapy and after radiotherapy respectively. Results:The local control rate of test group(CR) was 78.3%, while it was 73.3% in control group, there were no obvious difference(P>0.05).In the end of radiotherapy, CD3 +,CD4 +, CD4 +/CD8 + descended, CD8 + ascended (P<0.01)in control group and these changed slightly in test group.The response(dizziness-alleviating) rate were 81.5% in test group and 44.8% in control group, The difference between these two groups was significant (P < 0.01). After starting radiotherapy, WBC was obviously decreased in control group, while the decrease was slight in test group.Conclusions:The combination of radiotherapy with SF injection may increase immunity function of patients and improve the patients's life quality, but can not promote the vanishing of carcinoma.
出处
《中国现代医学杂志》
CAS
CSCD
2003年第6期39-41,共3页
China Journal of Modern Medicine
